Fact CheckerSign in

NCT00046189Completed

Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

Cancer Risk in Xeroderma Pigmentosum Heterozygotes

Source: ClinicalTrials.gov · Last updated 8 Jan 2024

Brief summary (registry, in English)

This study will determine if family members of patients with xeroderma pigmentosum (XP) have various abnormalities, including: skin abnormalities; nervous system abnormalities, such as hearing problems; skin, eye, or internal cancers, or other changes. XP is a rare inherited disease that involves an inability to repair damage to cell DNA (genetic material). It can affect several organ systems, including the skin, eye, nervous system, and bones. Patients have a more than thousand-fold increase in frequency in all major skin cancers. Parents of patients with XP are carriers of the abnormal XP gene. Other family members may also be carriers of the abnormal XP gene. Carriers do not develop the disease themselves; symptoms develop only in children who have inherited the faulty gene from both parents. This study will try to clarify the genetic basis for XP and to understand the increased frequency of cancer in the disease. XP patients who have been evaluated at the NIH Clinical Center and their relatives are eligible for this study. Newly diagnosed XP patients are also eligible. Spouses of relatives will also be included as control subjects. Patients and their family members will undergo some or all of the following procedures: * Parental permission to review the child s relevant medical records and pathology material from treatments or surgery for cancer or other related illnesses * Medical history and physical examination, with particular attention to the skin and possible eye, hearing or neurological examinations * Photographs to document skin and other physical findings * Nuclear medicine scans to evaluate the brain and nervous system * X-rays of the skull or other parts of the body * Nervous system testing with an electroencephalogram (EEG), electroretinogram (ERG), electromyogram (EMG) or nerve conduction velocity measurement * Collection of blood and skin samples for gene studies * Establishment of cell lines from collected blood or tissues to study DNA repair, skin cancer, cancers related to XP, immune defects, and related studies. * Biopsy (surgical removal of a small piece of tissue) of suspicious skin lesions for examination under a microscope * Collection of a cheek cell sample, obtained by twirling a soft brush against the inside of the cheek * Collection of a hair sample for microscopic examination and composition analysis * Surgery to treat skin cancers or other lesions

Status (registry)
Completed
Study type
Observational
Enrollment
301 (actual)
First submitted
21 Sept 2002
Start date
7 Apr 2003
Primary completion date
5 Jan 2024
Lead sponsor
National Cancer Institute (NCI)
NCT number
NCT00046189

What you commit to

  • Study type: Observational
  • Participants enrolled: 301
  • From 7 Apr 2003 to the primary completion date, 5 Jan 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Lab values

  • -Inability or unwillingness to provide family history information or tissue (skin, blood, buccal cells or hair) for laboratory studies.

Criteria the registry did not label

  • INCLUSION CRITERIA:
    • Members of the XP families where the proband has previously been evaluated at the Clinical Center or is newly diagnosed under other approved protocols (primarily 99-C-0099) are eligible to participate in this study. Families with XP patients of any age (excluding neonates), gender or race are eligible for this study.
  • On referral, patients with XP and families of XP patients will be considered for inclusion in the study if the proband has clinical documentation of features of XP and laboratory determination of the DNA repair defect. All relatives of XP patients including spouses are eligible to participate. A spouse of a blood relative of a patient with xeroderma pigmentosum would also be eligible.
  • Ability of patient or Legally Authorized Representative (LAR) to sign a written informed consent document

Age in the registry: 1 month to 99 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
National Institutes of Health Clinical Center
Coordinator of this site? Confirm its status
BethesdaUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.